

Angiology

<http://ang.sagepub.com>

Hyperbaric Oxygen Therapy in Chronic Vascular Wound Management

F. Wattel, D. Mathieu, J.-M. Coget and V. Billard

Angiology 1990; 41; 59

DOI: 10.1177/000331979004100109

The online version of this article can be found at:
<http://ang.sagepub.com/cgi/content/abstract/41/1/59>

Published by:



<http://www.sagepublications.com>

Additional services and information for *Angiology* can be found at:

Email Alerts: <http://ang.sagepub.com/cgi/alerts>

Subscriptions: <http://ang.sagepub.com/subscriptions>

Reprints: <http://www.sagepub.com/journalsReprints.nav>

Permissions: <http://www.sagepub.com/journalsPermissions.nav>

Citations <http://ang.sagepub.com/cgi/content/refs/41/1/59>

**31st ANNUAL MEETING
INTERNATIONAL COLLEGE OF ANGIOLOGY
ROME, ITALY — JUNE, 1989
SYMPOSIUM PROCEEDINGS**

**Hyperbaric Oxygen Therapy in
Chronic Vascular Wound Management**

F. Wattel, M.D.
D. Mathieu, M.D.
J-M Coget, M.D., F.I.C.A.
and
V. Billard, M.D.

LILLE, FRANCE

Abstract

Many nonhealing tissues are hypoxic, with oxygen tensions frequently ranging from 5 to 15 mmHg. In such an environment, the normal wound healing sequence is disrupted or halted and phagocytic killing activity depressed. So the adjunctive use of hyperbaric oxygen (HBO), based on physiologic data and clinical observations, can provide the substrate necessary to initiate and sustain the healing process.

During a twelve-month period, 20 patients with a nonhealing wound were referred to the hyperbaric center: chronic arterial insufficiency ulcers in 9 cases, diabetic wounds (foot lesions) in 11 cases.

Adjunctive HBO therapy, initiated twice a day, consisted of pure oxygen, 2.5 ATA, 90 min. The average length of sessions was 46 (15-108). Complete

healing was observed in 15 of 20 cases.

The wound management can be helped with the transcutaneous oxygen measurements under hyperbaric oxygen. The distal TCPO₂ at 2.5 ATA pure oxygen is a reliable test to predict final outcome (healing or no change), when these values were not different in normal air and in normobaric oxygen:

Distal TCPO ₂	Healing		No Change
air	32 ± 31	NS	12 ± 4
1 ATA O ₂	75 ± 70	NS	18 ± 10
2 ATA O ₂	635 ± 388	p = 0.003	45 ± 20

In hyperbaric oxygen therapy, when the distal TCPO₂ value was inferior to 100 mmHg, all patients showed either no improvement or aggravation, and when the value was higher than 100mmHg, wound healing was achieved with all patients.

Introduction

Tissue oxygen pressure plays an important part in the wound-healing process. On the one hand, tissue oxygen tensions of 30 to 40 mmHg are necessary for fibroblastic proliferation, fibroblastic synthesis of collagen,¹⁻⁴ and for capillary proliferation.⁵⁻⁷ On the other hand, increased oxygen tensions enhance the bactericidal activity of white blood cells.⁸⁻⁹

Many nonhealing tissues are hypoxic, with oxygen tensions frequently ranging from 5 to 15 mmHg.¹⁰ In such an environment, the normal wound-healing sequence is disrupted or halted and phagocytic killing activity depressed, thus leading to infection, which aggravates the problem.

Consequently, "the adjunctive use of HBO, based on physiologic data and clinical observations, can provide the substrate necessary to initiate and sustain the healing process."¹¹

The present paper aims at providing: a clinical report on chronic vascular wounds, an approach to wound management with hyperbaric oxygen (HBO) treatment, and an assessment of transcutaneous oxygen measurements under hyperbaric oxygen in such cases.

Clinical Report on Chronic Vascular Wounds

The following report focuses on arterial insufficiency ulcers, venous stasis ulcers, and diabetic wounds.

The effects of HBO treatment on arterial insufficiency ulcers are reported in Table I. All the ulcers were refractory to conventional treatments before use of HBO. There is no difference between obstructive arteriosclerotic ulcers and ulcers of thromboangiitis obliterans in relation to the HBO response. Prolonged courses of HBO are necessary for healing (on average: thirty to fifty sessions), but the results are dependent on the characteristics of the wound (age, extent, depth, etc.). They are also dose dependent. In 60-70% of cases, ulcers healed completely. The period required for healing is often considerably reduced with split skin grafting once the ulcer base has been prepared with a course of HBO.

TABLE I
HBO in Arteriosclerotic Ulcers

Author(s)	Procedures	Cases	Healing	Improved
Kidokoro et al ²⁹	2.25 ATA O ₂ 20-70 sessions	22	12	
Hart and Strauss ¹⁵	2 ATA O ₂ 90 min	16	12	
Kizer et al ¹³	2 ATA O ₂ 90 min 11-117 sessions	22	5	4
Sakakibara et al ³⁰	2 ATA O ₂ 75 min 35-50 sessions	43		35
Barr and Perrins, ⁶	1.5 to 3 ATA O ₂ all geriatric patients—amputation avoided in 65%	50	26	10
Yephuni et al ³¹		370	192	113
Yagi ¹⁴	2 ATA O ₂ 90 min (25 sessions or more)	95	62	

In general, HBO is not recommended for venous stasis ulcers, for which success is achieved through venous surgery, lower extremity elevation, counterpressure, local support, wound care, and skin grafting. But occasionally, when failure in these procedures occurs, HBO is warranted. Bass,¹² using HBO at 2 atmospheres absolute (ATA), obtained complete healing in 17 of 19 cases, and Kizer and al,¹³ in 5 of 6 cases. Yagi¹⁴ reported 10 cases of stasis ulcers that received HBO before and after Linton's surgical procedure; no recurrence of the ulcer was observed in any of the cases over a period of about ten years.

Foot lesions (gangrene and perforating ulcer) are common problems in diabetic patients. Despite assiduous conventional treatment, they cause serious disability or amputation. The effectiveness of HBO in the treatment of the diabetic wounds has been reported by Hart and Strauss,¹⁵ Barr and Perrins,¹⁶ Emhoff and Myers,¹⁷ Pedesini et al,¹⁸ and Faglia et al.¹⁹

The HBO treatment has a cleansing effect that halts wound infection. The surrounding tissues are revived, allowing a plastic surgical intervention. In such cases, coordination with the surgeon is very important; HBO treatment will be prescribed before or immediately after the surgical operation.

Hart and Strauss¹⁵ treated 11 patients with diabetic ulcers, using HBO at 2 ATA; all of them showed a fair response. Barr and Perrins¹⁶ treated 24 patients with diabetic ulcer by using HBO; 67% of the ulcers healed, and in 18% of cases, amputation was avoided. In 26 cases affected by diabetic vasculopathies with soft-tissue ulcer (65%), finger or foot gangrene (25%), and lower limb gangrene (10%), Pedesini et al¹⁸ observed good results in 88.6% of cases. The average number of HBO sessions was 34.3 per patient. The healing period was significantly shortened in all cases. Faglia et al¹⁹ treated 26 hospitalized adult diabetic subjects, all with microangiopathies and affected by foot lesions, with a combination of strict metabolic control, daily curettage, and HBO. A control group of 20 insulin-treated microangiopathic diabetic subjects presenting foot gangrene (comparable age and duration of disease) was treated with metabolic control and daily curettage. In HBO-treated patients, healing of lesions was obtained in 24/26 cases; 2/26 worsened and later had amputations. In the control group, 2/20 patients improved, 10/20 patients were unchanged, and 8/20 worsened and had amputations. Comparison between the two groups (Chi-square test) revealed a highly significant difference.

Clinical Management with HBO treatment

"HBO therapy for difficult wounds should be undertaken with the clear understanding that it must be part of the vigorous, coordinated surgical team approach to total patient management."¹¹

At first, a careful physical examination with particular reference to peripheral circulation is necessary. Noninvasive methods such as determination of lower extremity perfusion pressure,^{20,21} oscillometry before and after effort with determination of the Pourcelot index, Doppler and Doppler laser evaluation, and phlethysmographic measurements may help to determine which patients are eligible for HBO treatment.

In some cases, arteriography should be applied to determine whether reconstruction vascular surgery should be performed prior to HBO treatment.

Transcutaneous evaluation of tissue oxygen tension in response to HBO breathing may also indicate whether oxygen should be delivered to the wound in a dose adequate to promote healing.

Regular and aggressive daily debridement of the wound is absolutely required as HBO therapy progresses; if necessary, debridement is effected under anesthesia.

Daily wound care and dressing changes are necessary to ensure a proper environment for capillary budding and epithelialization. The use of toxic agents, such as nonspecific antiseptics, is to be avoided.

Once a capillary base has been established, epithelialization will usually occur, but split skin grafting may be indicated to close the wound; hence, the period required for healing can be reduced considerably if the ulcer base has been prepared with a course of HBO. Nutritional status and metabolic control are important for a successful outcome.

TcPO₂ measurements under HBO are warranted for effective follow-ups. Wound healing may take a long time, and besides, patients should be considered for therapy on a case-by-case basis.

Assessment of Transcutaneous Measurements Under Hyperbaric Oxygen Prediction of Final Outcome of Nonhealing Wounds

Transcutaneous oxygen monitoring has been used in patients with peripheral vascular disease.²³⁻²⁵ In these cases, transcutaneous oxygen monitoring has been shown to reflect tissue perfusion. Transcutaneous oxygen pressure of more than 50 torr has been defined to be predictive of a favorable outcome, when values inferior to 40 torr are associated with amputation.²⁶

Sheffield^{10,27,28} has demonstrated that problem wounds are often hypoxic and that oxygen is delivered to problem wounds during a course of hyperbaric oxygen treatment with elevation of wound oxygen tension. Unfortunately, however, specific oxygen dose requirements for individual patients have not yet been defined. In a series of 11 diabetic patients, below-knee lesions with TcPO₂ values inferior to 20 mmHg were shown to heal during a course of HBO treatment, if a TcPO₂ value of 900-1000 mmHg could be achieved upon initial exposure to 100% oxygen breathing at 2.4 ATA.¹⁷

Because it was not possible to find predictive values in chronic vascular wound treatment, we undertook a study to evaluate the usefulness of transcutaneous oxygen measurements at different oxygen pressures.

Patients and Methods

During a twelve-month period, 20 patients with a nonhealing wound were referred to our hyperbaric center: chronic arterial insufficiency ulcers in 9 cases, diabetic wounds (foot lesions) in 11 cases.

Adjunctive HBO therapy, initiated twice a day, consisted of pure oxygen at 2.5 ATA for 90 minutes. The average number of sessions was 46 (15-108). Complete healing was observed in 15 of 20 cases.

Transcutaneous oxygen measurements were taken by using a miniature electrode. The instrument is calibrated before each use. Final readings are taken after equilibration. Simultaneous readings are recorded from two sensors placed bilaterally on the extremities, near the wound, in a mirror fashion. The reference electrode is put in the upper front part of the thorax. These measurements are taken in three successive conditions: patient breathing at first normal air, then normobaric pure oxygen by facial mask, and finally, 2.5 ATA hyperbaric pure oxygen.

Results

Four different data are of interest.

1. If we consider the TcPO₂ reference as the absolute value (mmHg), there was no significant difference between transcutaneous oxygen pressures of patients who were healed and those who were not, whether patients breathed normal air, pure oxygen, or hyperbaric oxygen (air: 55 ± 28 vs 43 ± 19 ; 1 ATA O₂: 151 ± 57 vs 104 ± 51 ; 2.5 ATA O₂: 829 ± 197 vs 926 ± 109). (Figure 1) Such results show that a similar take of oxygen was consumed in the two groups.

By contrast, the distal TcPO₂ absolute value was measured in normal air, pure oxygen, or hyperbaric oxygen. The transcutaneous oxygen pressures in hyperbaric oxygen were significantly different according to outcome (healing or no change) when these values were not different in normal air and in normobaric oxygen: (air: 32 ± 31 vs 12 ± 4 ; NS; 1 ATA O₂: 75 ± 70 vs 18 ± 10 , NS; 2.5 ATA O₂: 653 ± 388 vs 45 ± 20 , $p = 0.003$). (Figure 2)

2. If we consider the difference between transcutaneous oxygen pressure in 2.5 ATA pure oxygen and in normal air, there was a significant difference between successful and unsuccessful outcomes: 621 ± 390 vs 33 ± 18 , $p = 0.004$. But there was no difference at 1 ATA pure oxygen: 42 ± 50 vs 6.6 ± 11.2 , NS. (Figure 3)

3. If we consider the ratio between distal TcPO₂ and TCPO₂ reference, in normal air, pure oxygen, and hyperbaric oxygen, only the ratio obtained with hyperbaric oxygen measurements results in a predictive outcome with a significant value: (ratio air: 0.597 ± 0.48 vs 0.30 ± 0.12 , NS; ratio 1 ATA O₂: 0.52 ± 0.47 vs 0.25 ± 0.33 , NS; ratio 2.5 ATA O₂: 0.80 ± 0.43 vs 0.0043 ± 0.016 , $p = 0.001$). (Figure 4)

4. If we consider the meaning of these different criteria, distal TcPO₂ and the ratio distal TcPO₂/TcPO₂ reference, in normal air and in pure oxygen, are not good predictors. But in




FIG. 1. TcPO₂ Reference (mmHg)




FIG. 2. Distal TcPO₂ (mmHg)




FIG. 3. (left) 1 ATA; FIO₂ 100%—Air; (right) 2.5 ATA; FIO₂ 100%—Air




FIG. 4. Distal TcPO₂/TcPO₂ Reference

hyperbaric oxygen, when the distal TcPO₂ value was lower than 100 mmHg, all patients showed either improvement or aggravation, and when the value was higher than 100 mmHg, wound healing was achieved with all patients. In hyperbaric oxygen, when the distal TcPO₂ value was lower than 50 mmHg, the condition of all patients worsened. The interval between 50 and 100 mmHg of distal TcPO₂ value is, for us, the specific range in which hyperbaric oxygen therapy is the most strongly indicated, because only repeated measurements of distal TcPO₂ can predict a good evolution of the chronic vascular wound.

Conclusion

Chronic vascular wound management with hyperbaric oxygen therapy can thus be helped with the transcutaneous oxygen measurements under hyperbaric oxygen. The distal TcPO₂ at 2.5 ATA pure oxygen is a reliable test to predict final outcome with wound healing. Further studies will be necessary to confirm this assessment.

Acknowledgement

This study has been supported by the "Laboratoire Lafon," Maisons Alfort Cedex, France.

*F.E. Wattel, M.D.
CHR De Lille Hyperbare
Centre Regional D'Oxygenotherapie
Hopital Albert Calmette
Boulevard du Professeur J. Leclercq
F-59033 Lille, Cedex, France*

References

1. Winter GD, Perrins DJD: Effects of hyperbaric oxygen treatment on epidermal regeneration. Proceedings of the Fourth International Congress on Hyperbaric Medicine, ed. by Wada J, Iwa T. Baltimore: William and Wilkins, 1970, p 363.
2. Hunt TK, Pai MP: The effect of varying ambient oxygen tensions on wound metabolism and collagen synthesis. *Surg Gynecol Obstet* 135:561-567, 1972.
3. Ninikoski J, Hunt TK: Oxygen tension in human wounds. *J Surg Res* 12:72-82, 1972.
4. Knighton DR, Sivers JA, Hunt TK: Regulation of wound healing: Effect of oxygen gradients and inspired oxygen concentrations. *Surgery* 90:262-270, 1981.
5. Ketchum FA, Thomas AN, Hall AD: Angiographic studies of the effects of hyperbaric oxygen on burn wound revascularization. In: Proceedings of the Fourth International Congress on Hyperbaric Medicine, ed. by Wada J, Iwa T. Baltimore: Williams and Wilkins, 1970, pp 383-394.
6. Manson PN, Im MJ, Myers RAM, et al: Improved capillaries in skin flaps. *Surg Forum* 31:564-566, 1980.
7. Meltzer T, Myers B: The effect of hyperbaric oxygen on the bursting strength and rate of vascularization of skin wounds in the rat. *Am Surg* 52:659-662, 1986.
8. Mader JT, Brown GL, Guckian JC, et al: A mechanism for the amelioration by hyperbaric oxygen of experimental staphylococcal osteomyelitis in rabbits. *J Infect Dis* 142:915-922, 1980.
9. Mader JT: Phagocytic killing and hyperbaric oxygen: Antibacterial mechanisms. *HBO Rev* 2:37-49, 1981.
10. Sheffield PJ, Dunn JM: Continuous monitoring of tissue oxygen tension during hyperbaric oxygen therapy. In: Proceedings of the Sixth International Congress on Hyperbaric Medicine, ed. by Smith G. Aberdeen: Aberdeen University Press, 1977, pp 125-129.
11. HBO. A Committee report of UHMS, revised 1986.
12. Bass BH: The treatment of varicose leg ulcers by hyperbaric oxygen. *Postgrad Med J* 46:40, 1970.
13. Kizer KW, Kramm J, Dobbs L: Hyperbaric oxygen therapy of refractory skin ulcers. In: Proceeding of the VIIth Annual Conference on Clinical Applications of HBO. Anaheim, California, June, 1982.
14. Yagi H: On the hyperbaric oxygen therapy for severe infected granulation wounds (ulcers) of upper and lower extremities. *Jpn Hyperbar Med* 22:27-40, 1987.
15. Hart GB, Strauss MB: Responses of ischaemic ulcerative conditions to OHB. In hyperbaric medicine, ed. by Smith G. Aberdeen: Aberdeen University Press, pp 312-314, 1979.
16. Barr PO, Perrins DJD: Prolonged use of hyperbaric oxygen (HBO) in undulant uclers of the leg. Proceeding of the Eighth International Congress on Hyperbaric Medicine, 1984, pp 217-222, Best Publishing Company, 1987.
17. Emhoff TA, Myers RAM: Transcutaneous oxygen measurements and wound healing. Baltimore: Maryland Institute for Emergency Medical Services Systems, 1984.
18. Pedesini G, Oriani G, Barnini C, et al: Hyperbaric oxygen therapy in the treatment of diabetic vasculopathies. In: Proceeding of the IX Congress of EUBS, Edicions CREIS, 1984, pp 207-212.
19. Faglia E, Baroni G, Favales F, et al: Traitement de la grangène diabétique par l'oxygène hyperbare. Journées de diabétologie de l'Hôtel Dieu. Paris: Ed. Flammarion Medicine Sciences, 1987, pp 209-216.
20. Carter SA: The relationship of distal systolic pressures to healing of skin lesions in limbs with arterial occlusive disease with special reference to diabetes mellitus. *Scand J Clin Invest* 128 (suppl):239-243, 1973.
21. Marroni A, Campanella M, De Sanctis S, et al: Hyperbaric oxygen therapy of chronic refractory leg ulcers. *J Hyperbaric Med* 1:4, 1986.
22. Fredenucci P: Oxygénothérapie hyperbare et artériopathies. *J Mal Vasculaire* 10:166-172, 1985.
23. Hauser CJ, Shoemaker WC: Use of a transcutaneous PO₂ regional perfusion index to quantify tissue perfusion in peripheral vascular disease. *Am Surg* 197:337-343, 1983.
24. Kram MB, Shoemaker WC: Use of transcutaneous O₂ monitoring in the intraoperative management of severe peripheral vascular disease. *Crit Care Med* 11:482-483, 1983.
25. Wyss CA, Matsen FA III, Simmons CW, et al: Transcutaneous oxygen tension in measurements on limbs of diabetic and non diabetic patients with peripheral vascular disease. *Surgery* 95:339-345, 1984.
26. White, RA, Wolan L, Harlet D, et al: Noninvasive evaluation of peripheral vascular disease using transcutaneous oxygen tension. *Am J Surg* 144:68-75, 1982.
27. Sheffield PJ: Tissue oxygen measurements with respect to soft-tissue wound healing with normobaric and hyperbaric oxygen. *HBO Rev* 6:18-46, 1985.
28. Sheffield PJ: Tissue Oxygen Measurements in "Problem Wounds"—The Role of Oxygen," ed. by Davis JC, Hunt TK. Amsterdam: Elsevier, 1988, pp 17-51.
29. Kidokoro M, Sakakiba K, Rakao T, et al: Experimental and clinical studies upon hyperbaric oxygen therapy for peripheral vascular disorders. In: Hyperbaric Medicine, ed. by Wada J, Iwa T. Baltimore: Williams and Wilkins, 1969, pp 462-468.
30. Sakakibara K, Takahashi H, Kobayashi S: The role of hyperbaric oxygen therapy in the salvage of ischemic limbs from inevitable amputation in chronic peripheral vascular disease with particular reference to those having had unsuccessful surgery. Proceedings of the Eighth International Congress on Hyperbaric Medicine, 1984, Best Publishing Company, 1987, pp 221-228.
31. Yephuni Sn, Lyskin GI, Fokina TS: Hyperbaric oxygenation in treatment of peripheral vascular disorders. *Int Angiol* 4:207-209, 1985.